Current Concepts of Pathogenesis and Treatment of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms

 

 Permissions and Reprints

Abstract

Philadelphia chromosome-negative myeloproliferative neoplasms are hematopoietic stem cell disorders characterized by dysregulated proliferation of mature myeloid blood cells. They can present as polycythemia vera, essential thrombocythemia, or myelofibrosis and are characterized by constitutive activation of JAK2 signaling. They share a propensity for thrombo-hemorrhagic complications and the risk of progression to acute myeloid leukemia. Attention has also been drawn to JAK2 mutant clonal hematopoiesis of indeterminate potential as a possible precursor state of MPN. Insight into the pathogenesis as well as options for the treatment of MPN has increased in the last years thanks to modern sequencing technologies and functional studies. Mutational analysis provides information on the oncogenic driver mutations in JAK2, CALR, or MPL in the majority of MPN patients. In addition, molecular markers enable more detailed prognostication and provide guidance for therapeutic decisions. While JAK2 inhibitors represent a standard of care for MF and resistant/refractory PV, allogeneic hematopoietic stem cell transplantation remains the only therapy with a curative potential in MPN so far but is reserved to a subset of patients. Thus, novel concepts for therapy are an important need, particularly in MF. Novel JAK2 inhibitors, combination therapy approaches with ruxolitinib, as well as therapeutic approaches addressing new molecular targets are in development. Current standards and recent advantages are discussed in this review.

Publication History

Received: 04 February 2021

Accepted: 17 March 2021

Article published online:
30 June 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

• References

• 1 Spivak JL. Myeloproliferative neoplasms. N Engl J Med 2017; 376 (22) 2168-2181
  CrossrefPubMedGoogle Scholar
• 2 Rampal R, Al-Shahrour F, Abdel-Wahab O. et al. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood 2014; 123 (22) e123-e133
  CrossrefPubMedGoogle Scholar
• 3 Verstovsek S, Mesa RA, Gotlib J. et al; COMFORT-I Investigators. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol 2017; 10 (01) 55
  CrossrefPubMedGoogle Scholar
• 4 Brkic S, Meyer SC. Challenges and perspectives for therapeutic targeting of myeloproliferative neoplasms. HemaSphere 2020; 5 (01) e516
  CrossrefPubMedGoogle Scholar
• 5 Meyer SC, Levine RL. Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors. Clin Cancer Res 2014; 20 (08) 2051-2059
  CrossrefPubMedGoogle Scholar
• 6 Skoda RC, Duek A, Grisouard J. Pathogenesis of myeloproliferative neoplasms. Exp Hematol 2015; 43 (08) 599-608
  CrossrefPubMedGoogle Scholar
• 7 Jang MA, Seo MY, Choi KJ, Hong DS. A rare case of essential thrombocythemia with coexisting JAK2 and MPL driver mutations. J Korean Med Sci 2020; 35 (23) e168
  CrossrefPubMedGoogle Scholar
• 8 Beucher A, Dib M, Orvain C. et al. Next generation sequencing redefines a triple negative essential thrombocythaemia as double-positive with rare mutations on JAK2 V617 and MPL W515 hotspots. Br J Haematol 2019; 186 (05) 785-788
  CrossrefPubMedGoogle Scholar
• 9 James C, Ugo V, Le Couédic JP. et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434 (7037): 1144-1148
  CrossrefPubMedGoogle Scholar
• 10 Levine RL, Wadleigh M, Cools J. et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7 (04) 387-397
  CrossrefPubMedGoogle Scholar
• 11 Kralovics R, Passamonti F, Buser AS. et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352 (17) 1779-1790
  CrossrefPubMedGoogle Scholar
• 12 Baxter EJ, Scott LM, Campbell PJ. et al; Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365 (9464): 1054-1061
  CrossrefPubMedGoogle Scholar
• 13 Scott LM, Tong W, Levine RL. et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007; 356 (05) 459-468
  CrossrefPubMedGoogle Scholar
• 14 Pikman Y, Lee BH, Mercher T. et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006; 3 (07) e270-e270
  CrossrefPubMedGoogle Scholar
• 15 Pardanani AD, Levine RL, Lasho T. et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006; 108 (10) 3472-3476
  CrossrefPubMedGoogle Scholar
• 16 Klampfl T, Gisslinger H, Harutyunyan AS. et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013; 369 (25) 2379-2390
  CrossrefPubMedGoogle Scholar
• 17 Nangalia J, Massie CE, Baxter EJ. et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013; 369 (25) 2391-2405
  CrossrefPubMedGoogle Scholar
• 18 Elf S, Abdelfattah NS, Chen E. et al. Mutant calreticulin requires both its mutant C-terminus and the thrombopoietin receptor for oncogenic transformation. Cancer Discov 2016; 6 (04) 368-381
  CrossrefPubMedGoogle Scholar
• 19 Tefferi A, Lasho TL, Finke CM. et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia 2014; 28 (07) 1472-1477
  CrossrefPubMedGoogle Scholar
• 20 Cabagnols X, Favale F, Pasquier F. et al. Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients. Blood 2016; 127 (03) 333-342
  CrossrefPubMedGoogle Scholar
• 21 Lundberg P, Karow A, Nienhold R. et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood 2014; 123 (14) 2220-2228
  CrossrefPubMedGoogle Scholar
• 22 Grinfeld J, Nangalia J, Baxter EJ. et al. Classification and personalized prognosis in myeloproliferative neoplasms. N Engl J Med 2018; 379 (15) 1416-1430
  CrossrefPubMedGoogle Scholar
• 23 Abdel-Wahab O, Pardanani A, Patel J. et al. Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia 2011; 25 (07) 1200-1202
  CrossrefPubMedGoogle Scholar
• 24 Rampal R, Ahn J, Abdel-Wahab O. et al. Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. Proc Natl Acad Sci U S A 2014; 111 (50) E5401-E5410
  CrossrefPubMedGoogle Scholar
• 25 Emanuel RM, Dueck AC, Geyer HL. et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol 2012; 30 (33) 4098-4103
  CrossrefPubMedGoogle Scholar
• 26 Arber DA, Orazi A, Hasserjian R. et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127 (20) 2391-2405
  CrossrefPubMedGoogle Scholar
• 27 Thiele J, Kvasnicka HM, Müllauer L, Buxhofer-Ausch V, Gisslinger B, Gisslinger H. Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification. Blood 2011; 117 (21) 5710-5718
  CrossrefPubMedGoogle Scholar
• 28 Busque L, Patel JP, Figueroa ME. et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet 2012; 44 (11) 1179-1181
  CrossrefPubMedGoogle Scholar
• 29 Jaiswal S, Fontanillas P, Flannick J. et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 2014; 371 (26) 2488-2498
  CrossrefPubMedGoogle Scholar
• 30 Malcovati L, Gallì A, Travaglino E. et al. Clinical significance of somatic mutation in unexplained blood cytopenia. Blood 2017; 129 (25) 3371-3378
  CrossrefPubMedGoogle Scholar
• 31 Jaiswal S, Natarajan P, Silver AJ. et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med 2017; 377 (02) 111-121
  CrossrefPubMedGoogle Scholar
• 32 McKerrell T, Park N, Chi J. et al. JAK2 V617F hematopoietic clones are present several years prior to MPN diagnosis and follow different expansion kinetics. Blood Adv 2017; 1 (14) 968-971
  CrossrefPubMedGoogle Scholar
• 33 Barbui T, Tefferi A, Vannucchi AM. et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia 2018; 32 (05) 1057-1069
  CrossrefPubMedGoogle Scholar
• 34 Landolfi R, Marchioli R, Kutti J. et al; European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004; 350 (02) 114-124
  CrossrefPubMedGoogle Scholar
• 35 Marchioli R, Finazzi G, Specchia G. et al; CYTO-PV Collaborative Group. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 2013; 368 (01) 22-33
  CrossrefPubMedGoogle Scholar
• 36 Barbui T, Masciulli A, Marfisi MR. et al. White blood cell counts and thrombosis in polycythemia vera: a subanalysis of the CYTO-PV study. Blood 2015; 126 (04) 560-561
  CrossrefPubMedGoogle Scholar
• 37 Gangat N, Strand J, Li CY, Wu W, Pardanani A, Tefferi A. Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation. Br J Haematol 2007; 138 (03) 354-358
  CrossrefPubMedGoogle Scholar
• 38 Passamonti F, Rumi E, Pietra D. et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia 2010; 24 (09) 1574-1579
  CrossrefPubMedGoogle Scholar
• 39 Barosi G, Birgegard G, Finazzi G. et al. A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. Br J Haematol 2010; 148 (06) 961-963
  CrossrefPubMedGoogle Scholar
• 40 Kiladjian JJ, Cassinat B, Chevret S. et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008; 112 (08) 3065-3072
  CrossrefPubMedGoogle Scholar
• 41 Gisslinger H, Klade C, Georgiev P. et al; PROUD-PV Study Group. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol 2020; 7 (03) e196-e208
  CrossrefPubMedGoogle Scholar
• 42 Vannucchi AM, Kiladjian JJ, Griesshammer M. et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 2015; 372 (05) 426-435
  CrossrefPubMedGoogle Scholar
• 43 Passamonti F, Griesshammer M, Palandri F. et al. Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. Lancet Oncol 2017; 18 (01) 88-99
  CrossrefPubMedGoogle Scholar
• 44 Rocca B, Tosetto A, Betti S. et al. A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia. Blood 2020; 136 (02) 171-182
  CrossrefPubMedGoogle Scholar
• 45 Alvarez-Larrán A, Pereira A, Guglielmelli P. et al. Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation. Haematologica 2016; 101 (08) 926-931
  CrossrefPubMedGoogle Scholar
• 46 Barbui T, Finazzi G, Carobbio A. et al. Development and validation of an international prognostic score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood 2012; 120 (26) 5128-5133 , quiz 5252
  CrossrefPubMedGoogle Scholar
• 47 Haider M, Gangat N, Lasho T. et al. Validation of the revised international prognostic score of thrombosis for essential thrombocythemia (IPSET-thrombosis) in 585 Mayo Clinic patients. Am J Hematol 2016; 91 (04) 390-394
  CrossrefPubMedGoogle Scholar
• 48 Passamonti F, Thiele J, Girodon F. et al. A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. Blood 2012; 120 (06) 1197-1201
  CrossrefPubMedGoogle Scholar
• 49 Carobbio A, Antonioli E, Guglielmelli P. et al. Leukocytosis and risk stratification assessment in essential thrombocythemia. J Clin Oncol 2008; 26 (16) 2732-2736
  CrossrefPubMedGoogle Scholar
• 50 Carobbio A, Ferrari A, Masciulli A, Ghirardi A, Barosi G, Barbui T. Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis. Blood Adv 2019; 3 (11) 1729-1737
  CrossrefPubMedGoogle Scholar
• 51 Harrison CN, Campbell PJ, Buck G. et al; United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005; 353 (01) 33-45
  CrossrefPubMedGoogle Scholar
• 52 Gisslinger H, Gotic M, Holowiecki J. et al; ANAHYDRET Study Group. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood 2013; 121 (10) 1720-1728
  CrossrefPubMedGoogle Scholar
• 53 Gisslinger H, Buxhofer-Ausch V, Hodisch J. et al. A phase III randomized, multicentre, double blind, active controlled trial to compare the efficacy and safety of two different anagrelide formulations in patients with essential thrombocythaemia - the TEAM-ET 2·0 trial. Br J Haematol 2019; 185 (04) 691-700
  CrossrefPubMedGoogle Scholar
• 54 Harrison CN, Mead AJ, Panchal A. et al. Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide. Blood 2017; 130 (17) 1889-1897
  CrossrefPubMedGoogle Scholar
• 55 O'Sullivan JM, Hamblin A, Yap C. et al. The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinib. Blood 2019; 134 (23) 2107-2111
  CrossrefPubMedGoogle Scholar
• 56 Tefferi A. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management. Am J Hematol 2021; 96 (01) 145-162
  CrossrefPubMedGoogle Scholar
• 57 Passamonti F, Cervantes F, Vannucchi AM. et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010; 115 (09) 1703-1708
  CrossrefPubMedGoogle Scholar
• 58 Gangat N, Caramazza D, Vaidya R. et al. DIPSS plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011; 29 (04) 392-397
  CrossrefPubMedGoogle Scholar
• 59 Guglielmelli P, Lasho TL, Rotunno G. et al. MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis. J Clin Oncol 2018; 36 (04) 310-318
  CrossrefPubMedGoogle Scholar
• 60 Tefferi A, Guglielmelli P, Lasho TL. et al. MIPSS70+ version 2.0: mutation and karyotype-enhanced international prognostic scoring system for primary myelofibrosis. J Clin Oncol 2018; 36 (17) 1769-1770
  CrossrefPubMedGoogle Scholar
• 61 Tefferi A, Guglielmelli P, Nicolosi M. et al. GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. Leukemia 2018; 32 (07) 1631-1642
  CrossrefPubMedGoogle Scholar
• 62 Cervantes F, Isola IM, Alvarez-Larrán A, Hernández-Boluda JC, Correa JG, Pereira A. Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results. Ann Hematol 2015; 94 (11) 1791-1796
  CrossrefPubMedGoogle Scholar
• 63 Verstovsek S, Mesa RA, Gotlib J. et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012; 366 (09) 799-807
  CrossrefPubMedGoogle Scholar
• 64 Harrison C, Kiladjian J-J, Al-Ali HK. et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012; 366 (09) 787-798
  CrossrefPubMedGoogle Scholar
• 65 Verstovsek S, Gotlib J, Mesa RA. et al. Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. J Hematol Oncol 2017; 10 (01) 156
  CrossrefPubMedGoogle Scholar
• 66 Martínez-Trillos A, Gaya A, Maffioli M. et al. Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients. Ann Hematol 2010; 89 (12) 1233-1237
  CrossrefPubMedGoogle Scholar
• 67 Geyer HL, Dueck AC, Scherber RM, Mesa RA. Impact of inflammation on myeloproliferative neoplasm symptom development. Mediators Inflamm 2015; 2015: 284706
  CrossrefPubMedGoogle Scholar
• 68 Kleppe M, Kwak M, Koppikar P. et al. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. Cancer Discov 2015; 5 (03) 316-331
  CrossrefPubMedGoogle Scholar
• 69 Porpaczy E, Tripolt S, Hoelbl-Kovacic A. et al. Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy. Blood 2018; 132 (07) 694-706
  CrossrefPubMedGoogle Scholar
• 70 Tefferi A, Pardanani A. Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clin Proc 2011; 86 (12) 1188-1191
  CrossrefPubMedGoogle Scholar
• 71 Palandri F, Palumbo GA, Elli EM. et al. Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis. Blood Cancer J 2021; 11 (01) 4
  CrossrefPubMedGoogle Scholar
• 72 Kröger NM, Deeg JH, Olavarria E. et al. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group. Leukemia 2015; 29 (11) 2126-2133
  CrossrefPubMedGoogle Scholar
• 73 Pardanani A, Harrison C, Cortes JE. et al. Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial. JAMA Oncol 2015; 1 (05) 643-651
  CrossrefPubMedGoogle Scholar
• 74 Harrison CN, Schaap N, Vannucchi AM. et al. Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: an updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure. Am J Hematol 2020; 95 (06) 594-603
  CrossrefPubMedGoogle Scholar
• 75 Mullally A, Hood J, Harrison C, Mesa R. Fedratinib in myelofibrosis. Blood Adv 2020; 4 (08) 1792-1800
  CrossrefPubMedGoogle Scholar
• 76 Harrison CN, Vannucchi AM, Platzbecker U. et al. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. Lancet Haematol 2018; 5 (02) e73-e81
  CrossrefPubMedGoogle Scholar
• 77 Mascarenhas J, Hoffman R, Talpaz M. et al. Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial. JAMA Oncol 2018; 4 (05) 652-659
  CrossrefPubMedGoogle Scholar
• 78 Waibel M, Solomon VS, Knight DA. et al. Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors. Cell Rep 2013; 5 (04) 1047-1059
  CrossrefPubMedGoogle Scholar
• 79 Tefferi A, Lasho TL, Begna KH. et al. A pilot study of the telomerase inhibitor imetelstat for myelofibrosis. N Engl J Med 2015; 373 (10) 908-919
  CrossrefPubMedGoogle Scholar
• 80 Baerlocher GM, Oppliger Leibundgut E, Ottmann OG. et al. Telomerase inhibitor imetelstat in patients with essential thrombocythemia. N Engl J Med 2015; 373 (10) 920-928
  CrossrefPubMedGoogle Scholar